NCT03977233View on ClinicalTrials.gov

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 12, 2019

Primary Completion Date

July 31, 2027

Study Completion Date

January 31, 2030

Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)Cancer of PancreasPancreatic Cancer, AdultPancreas AdenocarcinomaPancreatic NeoplasmsPancreatic Cancer Non-resectablePancreatic Cancer Resectable
Interventions
DRUG

Oxaliplatin

85 mg/m2 in 250 cc Dextrose solution given by IV on Day 1 of each 14-day cycle

DRUG

Leucovorin

400 mg/m2 in 100 cc dextrose solution given with irinotecan by IV on Day 1 of each 14-day cycle

DRUG

Irinotecan Hydrochloride

180 mg/m2 in 500cc dextrose solution given with leucovorin by IV on Day 1 of each 14-day cycle

DRUG

5-FU

400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion on Day 1 of each 14-day cycle

Trial Locations (1)

27599

RECRUITING

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill

All Listed Sponsors
lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT03977233 - Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter